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INTRODUCTION
Invasive micropapillary carcinoma (IMPC) is a rare, clini-
cally aggressive variant of invasive ductal carcinoma that ac-
counts for 0.7-3% of all breast cancer cases. It is associated with 
a high incidence of axillary lymph node metastases, frequent 
local recurrence, and a poor clinical outcome. A diagnosis of 
IMPC was first described in the pathology literature by Petersen 
[1] in 1993, and it was newly listed in the World Health Organ- 
ization (WHO) classification of breast cancer in 2003. This 
carcinoma is characterized histopathologically by tubuloalveolar 
or pseudopapillary structures lacking a fibrovascular core and 
surrounded by clear, empty spaces [2-4]. While many studies 
have been carried out of IMPC that focus on pathologic find-
ings [3,5], to our knowledge, only a few studies focus on the 
radiologic findings of IMPC [2,5,6]. Therefore, we retrospec-
tively evaluated imaging and histopathologic findings including 
the immunohistochemical characteristics of IMPC.
METHODS
Seventy-three patients diagnosed with IMPCs from Novem-
ber 2001 to November 2010 were identified on the basis of a 
search of the pathologic database. On the basis of the surgical 
specimen, we excluded 9 patients diagnosed with invasive duc-
tal carcinoma (IDC) (n=8) and mucinous carcinoma (n=1), 
despite being diagnosed with IMPC on the basis of core or   
excisional biopsies. We excluded 6 patients who underwent 
core needle biopsy only without surgery. IMPC in this study 
included cases with a more than 90% IMPC component. There-
fore, we also excluded 26 cases that contained non-micropap-
illary components, such as IDC (n=18), invasive cribriform 
carcinoma (n=4), mucinous carcinoma (n=2), tubular carci-
noma (n=1), and microinvasive ductal carcinoma (n=1). Three 
further patients were excluded because radiologic images were 
not available for review. In total, 29 patients were enrolled in 
this study. 
For mammograms, craniocaudal and mediolateral oblique 
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Purpose: The purpose of this study is to evaluate imaging and 
histopathologic findings including the immunohistochemical 
characteristics of invasive micropapillary carcinoma (IMPC) of 
the breast. Methods: Twenty-nine patients diagnosed with IMPC 
were included in the present study. Mammographic, sonographic, 
and magnetic resonance imaging (MRI) findings were analyzed 
retrospectively according to the American College of Radiology 
Breast Imaging Reporting and Data System lexicon. 
18F-fluoro-
deoxyglucose positron emission tomography-computed tomog-
raphy (PET-CT) findings were also evaluated. Microscopic slides 
of surgical specimens were reviewed in consensus by two pathol-
ogists with a specialty in breast pathology. Results: Most IMPCs 
presented as a high density irregular mass with a non-circum-
scribed margin associated with microcalcifications on mammo- 
graphy, as an irregular hypoechoic mass with a spiculated margin 
on ultrasound, and as irregular spiculated masses with washout 
patterns on MRI. PET-CT showed a high maximum standardized 
uptake value (SUVmax) (mean, 11.2). Axillary nodal metastases 
were identified in 65.5% of the patients. Immunohistochemical 
studies showed high positivities for estrogen receptor and c-erbB-2 
(93.1% and 51.7%, respectively). Conclusion: Even though the 
imaging characteristics of IMPCs are not distinguishable from 
typical invasive ductal carcinomas, this tumor type frequently   
results in nodal metastases and high positivities for both estrogen 
receptor and c-erbB-2. The high SUVmax value that is apparent 
on PET-CT might be helpful in the diagnosis of IMPC.
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views were obtained using Mammomat 3000 (Siemens Medi-
cal Solutions, Solna, Sweden) and Lorad M3 (Hologic Inc., 
Boston, USA) mammography units. All mammograms and 
ultrasonograms were retrospectively reviewed in consensus 
by one radiologist with 5 years of experience in breast imaging 
and by one resident. Parenchymal patterns on mammograms 
were categorized as either one of the following: pattern 1, almost 
entirely fatty; pattern 2, scattered fibroglandular tissue; pattern 
3, heterogeneously dense; or pattern 4, extremely dense. Each 
mammographic lesion was analyzed according to mass char-
acteristics (i.e., shape, margin, and density), presence of archi-
tectural distortion, and type of microcalcification (according 
to the American College of Radiology [ACR] breast imaging 
reporting and data system [ACR BI-RADS] lexicon). 
Ultrasound (US) was performed using a HDI 5000 (Advanced 
Technology Laboratories, Bothell, USA) or iU22 (Philips           
Ultrasound, Bothell, USA) US systems with a 5-12 MHz linear 
probe. We examined both breasts and the axillary lymph nodes. 
US images were reviewed for shape, orientation, margin, bound-
ary, echogenicity, posterior acoustic features, and associated 
calcifications, and were categorized according to the ACR       
BI-RADS final assessment. The largest diameter obtained from 
either sagittal or transverse views was recorded as the maximum 
tumor diameter. On the basis of previous studies, we defined 
a metastatic axillary lymph node on US when the lymph node 
had at least one of the following findings: a mean longitudinal-
transverse axis ratio of less than 1.5; the presence of eccentric 
cortical thickening; or the loss of a central fatty hilum [7].
Magnetic resonance imaging (MRI) was performed using a 
1.5-T scanner (Signa Excite; GE Healthcare System, Milwau-
kee, USA) equipped with a breast coil. Images were acquired 
in axial plane with the following sequences: axial, T2-weighted, 
fat-suppressed, fast spin-echo imaging (TR/TE=5,000/86, a flip 
angle of 90°, a field of view [FOV] of 300 mm, an acquisition 
matrix of 256×256, the number of excitations [NEX] of 3, and 
a 4.5-mm slice thickness); pre- and post-contrast, axial, and T1-
weighted 3D fast spoiled gradient-recalled echo sequence with 
parallel volume imaging (VIBRANT; GE Healthcare System) 
(TR/TE=6.5/3.1, a flip angle of 10°, a FOV of 300 mm, an   
acquisition matrix of 350×350, a NEX of 1, and a 1.1-mm slice 
thickness). To provide image contrast, Gadodiamide (Omni- 
scan; GE Healthcare AS, Oslo, Norway) was administered 
with an intravenous bolus injection (0.2 mmol per kg of body 
weight) at 3 mL/sec. Imaging was performed before the pa-
tients were given the intravenous bolus injection of the con-
trast material and four times over a period of 7.3 minutes after 
the patients were given the injection. Image post-processing, 
using the first contrast-enhanced series, included subtraction 
of unenhanced images from enhanced images, sagittal refor-
mations, and 3D maximum-intensity projections. Interpreta-
tion of the degree and patterns of enhancement was performed 
by visual assessment. The feature of abnormal enhancement 
was classified according to the ACR BI-RADS MRI lexicon. 
Associated findings, such as nipple retraction, skin thickening, 
lymphadenopathy, hematoma, and invasion of the pectoralis 
muscle and chest wall, were recorded. 
18F-Fluorogeoxyglucose (FDG) PET-computed tomography 
(CT) imaging was performed using a Discovery ST-16 system 
(GE Medical Systems). After fasting for at least 6 hours, nor-
mal fasting blood glucose levels were determined to be <150 
mg/dL for all patients. Patients ingested more than 500 mL of 
fluid for adequate urination. An intravenous injection of 8.14 
MBq/kg (0.22 mCi/kg) of FDG was then given, and the sub-
ject rested for approximately 1 hour. Pre-contrast CT scanning 
was performed using 16-channel CT from the skull base to the 
upper thigh prior to PET. PET was then immediately conducted 
over the same body region using 5-7 bed positions with a 3- 
minute acquisition time per bed position. CT data were used 
for attenuation correction and anatomical correlation with the 
PET data. Data were evaluated on a workstation (Advanced 
Workstation, version 4.3; GE Medical Systems) by a nuclear 
medicine physician and a resident. PET scans were analyzed 
visually and semi-quantitatively. FDG uptake was considered 
to be abnormal on visual analysis when the uptake in the region 
of the primary tumor was substantially higher than the back-
ground uptake in the contralateral breast or axilla. The highest 
recorded FDG uptake was semi-quantitatively analyzed after 
being corrected for radioactive decay, according to the follow-
ing formula: maximum standardized uptake value (SUVmax)= 
mean region of interest activity (mCi/mL)/injected dose (mCi)/ 
body weight (g).
Microscopic slides of surgical specimens were reviewed in 
consensus by two pathologists with a specialty in breast pa-
thology. The presence of lymphovascular invasion and lymph 
node metastasis was evaluated, as well as the immunohisto-
chemical characteristics. Immunohistochemical analyses for 
estrogen receptor (ER), progesterone receptor (PR), and c-
erbB-2 were performed. Four sections were cut from the tissue 
microarray blocks and placed on coated slides. The slides were 
baked in an oven overnight at 55°C to enhance adhesion of the 
sections to the slides. Deparaffinization in xylene and graded 
alcohol followed. Prediluted antibodies against ER (1:240;   
Immunotech, Marseille, France), PR (1:240; Novocastra, New-
castle, UK), and c-erbB-2 (1:400; Dako, Glostrup, Denmark) 
were obtained from commercial sources. Immunolocalization 
was performed using an LSAB kit (Dako, Carpinteria, USA). 
All assays were carried out prospectively in an automated im-
munostainer (Dako, Carpinteria, USA). Antibody-antigen re-InvasiveMicropapillaryCarcinomaoftheBreast 59
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activity was visualized using diaminobenzidine and counter-
staining with Meyer’s hematoxylin. The status of ER, PR, and 
c-erbB-2 were evaluated according to the American Society of 
Clinical Oncology/College of American Pathologists (ASCO/
CAP) guidelines for immunohistochemistry. ER and PR are 
considered positive if there are at least 1% positive tumor nuclei. 
The immunohistochemical (IHC) staining for c-erbB-2 was 
scored as 0 (no staining), 1+ (weak, incomplete membrane 
staining in any proportion of tumor cells), 2+ (complete mem-
brane staining that is either nonuniform or weak in intensity 
but with obvious circumferential distribution in at least 10% 
of cells), or 3+ (uniform intense membrane staining of >30% 
of invasive tumor cells). And IHC staining results for c-erbB-2 
were categorized as nega- tive (0 or 1+), equivocal (2+), or posi-
tive (3+). Equivocal cases were studied by fluorescent in situ 
hybridization (FISH) to determine c-erbB-2 gene amplification. 
Two-color FISH was done on a 3 µm-thick consecutive     
microarray sections. Before hybridization, the sections were 
deparaffinized, air dried, and dehydrated in 100% ethanol       
after incubation at 56°C for 24 hours. Microarray slides were 
treated in wash buffer (Vysis Inc., Downers Grove, USA) for   
3 minutes after treatment with 0.2 N HCl for 20 minutes. Pre-
treatment solution (Vysis Inc.) at 80°C was applied for 30 min-
utes and the slides were washed with purified water. Slides were 
treated with wash buffer twice for 5 minutes serially. Immersed 
slides in protease solution (Vysis Inc.) at 37°C was applied for 
10 minutes and the slides were washed with wash buffer at 45-
50°C and air dried. Slides were fixed in 10% buffered formalin 
for 10 minutes and then washed with wash buffer at 45-50°C. 
For denaturation, slides were immersed in denaturation solu-
tion (Vysis Inc.) for 5 minutes at 72°C followed by dehydra-
tion with 70%, 85%, and 100% ethanol serially at 45-50°C. For 
hybridization, 20 µL LSI HER-2/CEP17 probe (PathVision
TM; 
Vysis Inc.) was applied and a coverslip was applied over the 
probe. After overnight hybridization at 37°C in a humidified 
chamber, the slides were washed with 72°C post-hybridization 
wash buffer (PHWB; Vysis Inc.) for 2 minutes. Nuclei were 
counterstained with 20 µL 4,6-diamino-2-phenylindole (DAPI; 
Vysis Inc.). The centromere 17 (CEP) and HER2 copy num-
bers were counted in the predominant tumor cell population. 
Hybridization signals were enumerated by the ratio of orange 
signals for c-erbB-2 to green signals for CEP in morphologically 
intact and nonoverlapping nuclei. At least 2.2 times more c-
erbB-2 signals than CEP17 signals in the tumor cells was con-
sidered as the criterion for c-erbB-2 amplification.
RESULTS
The mean age of the 29 patients in this study was 48.9 years 
(range, 27-73 years). Twenty-eight patients were women and 
1 patient was a man. The mean size of breast cancer on US was 
2.2 cm (range, 0.6-8.0 cm). The initial manifestation of cancer 
was a palpable mass in 19 patients (65.5%), a screening mam-
mographic abnormality in 7 patients (24.1%), nipple discharge 
in 1 patient (3.4%), a palpable mass with nipple discharge in     
1 patient (3.4%), and a regular, post-surgical follow-up for 1 
patient (3.4%). The location of breast cancer was on the left 
breast in 15 patients (51.7%), and on the right in 14 patients 
(48.3%).
In total, 24 patients underwent mammography and the mam-
mographic findings are presented in Table 1. Masses were noted 
in 13 patients (54.2%) (Figure 1A), asymmetry or focal asym-
metry was noted in 5 patients (20.8%), microcalcifications only 
without mass or asymmetry were observed in 5 patients (20.8 
%), and no abnormalities were found in 1 patient (4.2%). The 
most common findings for masses were an irregular shape (9 
of 13; 69.2%), a non-circumscribed margin (11 of 13; 84.6%), 
and a high density (12 of 13; 92.3%). Microcalcifications were 
visible in 16 patients (66.7%). The shape of microcalcifications 
was fine pleomorphic in 9 patients (56.3%) (Figure 2A), fine 
Table 1. Mammographic findings of invasive micropapillary carcinoma
Findings (n=24)    No. (%)
Negative 1 (4.2)
Mass 13 (54.2)
(Focal) asymmetry 5 (20.8)
Calcification only 5 (20.8)
Shape (n=13)   
   Round 1 (7.7)
   Oval 2 (15.4)
   Lobular 1 (7.7)
   Irregular 9 (69.2)
Margin (n=13)  
   Circumscribed 2 (15.4)
   Microlobulated 2 (15.4)
   Obscured 3 (23.1)
   Indistinct 1 (7.7)
   Spiculated 5 (38.5)
Density (n=13)  
   High density 12 (92.3)
   Iso density 1 (7.7)
Shape of associated microcalcifications (n=16)  
   Round  2 (12.5)
   Punctate 2 (12.5)
   Amorphous 1 (6.3)
   Fine pleomorphic 9 (56.3)
   Fine linear or fine linear branching 2 (12.5)
Distribution of microcalcifications (n=16)   
   Regional 1 (6.3)
   Clustered 6 (37.5)
   Linear 1 (6.3)
   Segmental 8 (50.0)60  SeUnYun,etal.
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linear or fine linear branching in 2 patients (12.5%), round in 2 
patients (12.5%), punctate in 2 patients (12.5%), and amorphous 
in 1 patient (6.3%). The distribution of microcalcifications was 
segmental in 8 patients (50.0%) (Figure 2A), clustered in 6 pa-
tients (37.5%), regional in 1 patient (6.3%), and linear in 1 pa-
tient (6.3%). 
US was performed on 29 patients and the sonographic fea-
tures of masses are presented in Table 2 (Figure 1B). The follow-
ing characteristics of masses were most common: an irregular 
shape in 25 patients (86.2%), a parallel orientation in 25 pa-
tients (86.2%), a spiculated margin in 17 patients (58.6%), an 
abrupt interface in 22 patients (75.9%), and hypoechoic pattern 
in 27 patients (93.1%). The posterior acoustic feature was nega- 
tive in 20 masses (69.0%) and posterior acoustic shadowing 
was present in 9 masses (31.0%). Associated findings were duc-
tal dilatation in 3 patients (10.3%) and lymphedema in 1 pa-
tient (3.4%). On the basis of the ACR BI-RADS final assess-
ment, 24 cases (82.8%) were classified as category 5 (i.e., highly 
suggestive of malignancy; Figures 1B, 2B); 4 cases (13.8%) as 
category 4 (i.e., suspicious abnormality); and 1 case (3.4%) as 
F
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Figure 1. An invasive micropapillary carcinoma in a 44-year-old woman with a palpable mass 
in the left breast. (A) Craniocaudal and mediolateral oblique mammograms show irregular, 
high-density masses with spiculated margins in the left upper outer quadrant (arrow). An 
enlarged lymph node with eccentric cortical thickening is seen in the axillary area (arrowhead). 
(B) B-mode image of the left breast shows an approximately 2.6 cm, irregular, hypoechoic 
mass with spiculated margins in the 1 o’clock position. (C) B-mode image of the left axilla shows an approximately 2.2 cm, enlarged lymph node with 
cortical thickening and obliteration of the central fat hilum, which suggests a metastatic lymph node. The lymph node was pathologically confirmed as 
metastasis. (D, E) Axial, dynamic, contrast-enhanced, T1-weighted MR images of the left breast 2 minutes (D) and 6 minutes (E) after contrast injec-
tion show an approximately 3.3 cm, heterogeneous, enhanced mass in the upper outer quadrant. The kinetic pattern was evaluated visually and showed 
a persistent pattern. (F) 
18F-FDG PET maximum intensity projection image shows a subtle increased glucose metabolism (SUVmax=4.6) in the left 
breast (arrow). Increased glucose metabolism (SUVmax=4.0) is seen in the left axillary lymph node (arrowhead). (G) Photomicrography shows clusters 
of tumor cells in a micropapillary arrangement that appears to be within clear spaces (H&E stain, ×100; Inlet: positive immunohistochemical stain for 
estrogen receptor, ×400).InvasiveMicropapillaryCarcinomaoftheBreast 61
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category 3 (i.e., probably benign finding). We evaluated axillary 
lymph nodes in 29 cases and 13 patients (44.8%) were suspected 
to have metastatic lymph nodes (Figure 1C). All of these 13 
patients were confirmed to have metastatic lymph nodes on 
pathological examination. Six patients with negative findings 
on the US of the axillary lymph node had metastatic lymph 
nodes on pathologic examination.
MRI was performed in 18 patients and findings are presented 
in Table 3. Enhanced masses were noted in 11 patients (61.1%) 
(Figure 1D, E), while non-mass-like enhancement was observed 
in 7 patients (38.9%) (Figure 2C). The most common mass 
features were an irregular shape (7 of 11; 63.6%), irregular mar-
gins (5 of 11; 45.5%), and heterogeneous internal enhance-
ment (9 of 11; 81.8%) (Figure 1D, E). All 7 patients who pre-
sented with non-mass-like enhancement showed segmental 
distribution, and 6 of these 7 patients (85.7%) presented with 
heterogeneous internal enhancement (Figure 2C). We per-
formed kinetic curve analysis on 15 patients. The most com-
mon pattern was a washout pattern in 6 patients (40.0%) (Fig-
ure 2C, D). Associated findings were nipple retraction in 1 pa-
tient (5.6%), hematoma in 1 patient (5.6%), and diffuse skin 
thickening in 1 patient (5.6%). 
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Figure 2. An invasive micropapillary carcinoma (IMPC) in a 60-year-old woman who 
underwent mammographic screening. (A) A magnified craniocaudal mammogram of 
the right breast shows multiple pleomorphic microcalcifications with a segmental   
distribution. (B) B-mode image of the right breast shows multiple hypoechoic masses 
with indistinct margins and segmental distributions in the twelve o’clock position (arrows). 
Note the calcifications within the mass (arrowheads). (C, D) Axial, dynamic, contrast-
enhanced, T1-weighted MR images of the left breast 2 minutes (C) and 6 minutes (D) 
after contrast injection show non-mass-like, heterogeneous enhancement with a seg-
mental distribution in the right lower outer quadrant. A kinetic curve analysis showed 
washout pattern (arrows). (E) Photomicrography shows tumor cells in glands or nests 
that appear in clear spaces associated with microcalcification foci (arrow) (H&E stain, 
×200; Inlet: positive immunohistochemical stain for estrogen receptor, ×200).
Table 2. Sonographic findings of invasive micropapillary carcinoma
Findings (n=29) No. (%)
Shape   
   Oval 3 (10.3)
   Round 1 (3.4)
   Irregular 25 (86.2)
Orientation  
   Parallel 25 (86.2)
   Not parallel 4 (13.8)
Margin   
   Circumscribed 3 (10.3)
   Indistinct 1 (3.4)
   Angular 5 (17.2)
   Microlobulated 3 (10.3)
   Spiculated 17 (58.6)
Lesion boundary  
   Abrupt interface 22 (75.9)
   Echogenic halo 7 (24.1)
Echo pattern  
   Anechoic 1 (3.4)
   Complex 1 (3.4)
   Hypoechoic 27 (93.1)
Posterior acoustic features  
   No posterior acoustic feature 20 (69.0)
   Shadowing 9 (31.0)62  SeUnYun,etal.
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18F-FDG PET-CT was performed in 16 patients and all pri-
mary cancers showed FDG uptake (Figure 1F). The mean 
SUVmax value of primary breast cancers was 11.2 (range, 2.2-
48.3). Axillary lymph nodes showed FDG uptake in 12 of 16 
patients, and metastases were suspected in 12 patients (75.0%) 
(Figure 1F). All of these 12 patients were confirmed to have 
metastatic lymph nodes on pathological examination. Four 
patients with negative finding on 
18F-FDG PET-CT of axillary 
lymph node had metastatic lymph nodes on pathologic exam- 
ination. In 2 patients, distant metastases to the liver, the lungs, 
bone, and intercostal muscles were seen.
Twenty-five patients underwent a modified radical mastec-
tomy and 4 patients underwent a lumpectomy. Of the 29 sur-
gical specimens, lymphovascular invasion was found in 27 
(93.1%), and axillary nodal metastases were identified in 19 
tumors (65.5%). The mean number of metastatic axillary lymph 
nodes was 6.6 (range, 1-23). Immunohistochemical analyses 
were available for 29 carcinomas. Study of primary breast can-
cer showed the expression of ERs in 93.1% of the cases (27 of 
29) (Figures 1G, 2E) and PRs in 58.6% of the cases (17 of 29). 
For the c-erbB-2, a IHC score of 0 was shown in 8 cases (27.6%), 
1+ in 4 cases (13.8%), 2+ in 5 cases (17.2%), and 3+ in 12 cases 
(41.4%). Three out of the 5 cases scored as 2+ showed gene 
amplification by FISH. Therefore, overexpression of the c-erbB-2 
protein was observed in 51.7% of the cases (15 of 29).
Follow-up information was available for 27 patients. The 
mean follow-up period was 26.7 months (range, 1-68 months). 
Recurrence was noted in 4 patients: 2 in contralateral breast 
tissues and 2 in liver, lung, brain, and bone. Of these latter 2 
patients, one died after 4 months while the other died after 32 
months. 
DISCUSSION
IMPC is an uncommon, clinically aggressive variant of IDC 
that accounts for 1.7-3% of all cases of breast cancer. In the 2003 
WHO classification of breast tumors, IMPC was listed as a sub-
type of invasive carcinoma; however, no percentage of the IMPC 
component within the tumor was proposed as a criterion for 
diagnosis [8]. In the literature, no consensus opinion has been 
reached regarding the amount of IMPC required to make a 
diagnosis and determine the type of IMPC [3,9]. Regardless of 
the extent of the micropapillary component, tumors with any 
amount of this unique histologic pattern have a more aggres-
sive clinical behavior and poorer prognosis with a high degree 
of lymph node involvement [2-4,9]. The most common clin- 
ical manifestation of IMPC is a palpable mass [2,5,6]. Similarly, 
we also found that palpable masses (19 of 29; 65.5%) were the 
most common clinical manifestation. Although only a few 
studies concerning IMPC imaging findings have been carried 
out, previous studies have reported that IMPCs may present 
as irregular, spiculated or indistinct, high-density masses on 
mammography, and as irregular, indistinct or microlobulated, 
hypoechoic masses on US [2,5,6]. In our study, masses were 
the most common finding on mammography (13 of 24; 54.2%), 
presenting as an irregular shape (9 of 13; 69.2%), a spiculated 
margin (5 of 13; 38.5%), and a high density (12 of 13; 92.3%) 
in most cases. Sonographic findings showed an irregular shape 
(25 of 29; 86.2%), a spiculated margin (17 of 29; 58.6%), a par-
allel orientation (25 of 29; 86.2%), hypoechoic pattern (27 of 
29; 93.1%), and an abrupt interface boundary (22 of 29; 75.9%) 
as the most common features. Our results are in agreement 
with previous studies where microcalcifications were reported 
in 43-68% of the cases [2,5,6]. We found that microcalcifica-
tions presented in 66.7% (16 of 24) of the patients, which is 
similar to the result of a study conducted by Kim et al. [6] in 
which a 68% prevalence was observed, and by Adrada et al. [2] 
in which a 66% prevalence was noted. The shape of microcalci-
fications was indeterminate or highly suggestive of malignancy 
in most cases (12 of 16, 75.0%). 
Only a few studies of MRI findings for IMPCs have been 
previously conducted [2,10]. In these studies, IMPCs presented 
as irregular, spiculated masses with early rapid initial enhance-
ment and delayed washout or plateau pattern in dynamic con-
trast-enhanced studies [2,10]. We performed MRI in 18 pa-
tients, and the most common findings were irregular masses 
(7 of 18; 38.9%) with irregular or spiculated margins (9 of 18; 
50.0%), and washout patterns (6 of 15; 40.0%) based on kinetic 
curve analysis. These results are similar to those reported in 
the previous studies.
To our knowledge, there are no other studies concerning 
Table 3. Magnetic resonance imaging findings of invasive micropapillary 
carcinoma
Findings (n=18) No. (%)
Mass            11
   Shape  
      Oval 2 (18.2)
      Lobular 2 (18.2)
      Irregular 7 (63.6)
   Margin  
      Smooth 2 (18.2)
      Irregular 5 (45.5)
      Spiculated 4 (36.4)
Non-mass              7 
Kinetic curve assessment at delayed phase (n=15)  
   Persistent 4 (26.7)
   Plateau 5 (33.3)
   Washout 6 (40.0)InvasiveMicropapillaryCarcinomaoftheBreast 63
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PET-CT findings of IMPCs. In our study, all 16 patients who 
were imaged with PET-CT showed FDG uptake in the primary 
breast cancer. Many previous studies have reported that there 
is a relationship between the SUV level and the following: his-
tologic nuclear grade, incidence of lymph node metastasis, and 
hormonal receptor status [9-12]. Furthermore, a high uptake 
of 
18F-FDG is predictive of a poor prognosis in patients with 
primary breast cancer; the mean SUVmax value of primary 
tumors with axillary metastases is significantly higher (range, 
4.1-7.4) than tumors with no axillary lymph node involvement 
or distant metastases (range, 2.8-5.2) [11-14]. In our study, the 
mean SUVmax value of the primary tumor was 11.2 (range, 
2.2-48.3). A high SUVmax value may suggest a poor prognosis 
for IMPCs. 
IMPCs have a high propensity for lymphatic and lymph nod-
al spread [1]. The aggressiveness of this cancer might be related 
to lymphotropism and the inverse polarity of tumor cell clus-
ters [1]. With breast IMPCs, many studies have reported the 
occurrence of lymphatic and lymph nodal spread, while a 69-
95% prevalence of axillary lymph node metastases was also 
reported [4,15-20]. Microscopic lymphatic vessel invasion is 
an independent adverse prognostic factor and is a marker of 
lymph node metastasis [4,15,19]. The frequency of lymphovas-
cular invasion is reported to be approximately 55-76% [4,6, 
20]. In our study, the frequency of lymph node metastasis was 
similar to that reported in the previous studies, which found 
the frequency to be 65.5% (19 of 29). 
IMPC is characterized by higher rates of ER and PR expres-
sion [4,16,19,21]. Although ER positivity is generally known 
to be associated with better differentiation of tumors and an 
improved outcome, IMPCs seem to be an exception [4]. Zeki-
oglu et al. [4] reported the percentages of ER and PR positivity 
to be 68% and 61%, respectively, for IMPCs. These results are 
surprisingly higher than those observed for IDCs. The reported 
prevalence of c-erbB-2 and p53 proteins (54% and 48%, respec-
tively) was slightly higher than those of common breast cancers 
[4]. Walsh and Bleiweiss [19] reported high percentages of ER 
and PR positivity (90% and 70%, respectively) and nearly dou-
ble the expected percentage of c-erbB-2 positivity (60%). In 
our study, the expressions of ER (27 of 29; 93.1%) and c-erbB-2 
(15 of 29; 51.7%) were high, and similar to the results of the 
aforementioned studies [4,19]. Although many studies report 
higher incidences of ER and PR positivity for IMPCs, some 
studies have reported a lower frequency of ER expression for 
IMPCs [15]. These studies claim that some prognostic mark-
ers, such as ER, PR, p53, and c-erbB-2, cannot discriminate 
IMPCs from other breast cancers [4,15]. Hormone receptor 
status is one of the important prognostic factors for breast can-
cer and it has an important role in determining postoperative 
adjuvant therapy [22]. Positivities of p53 and c-erbB-2 are asso-
ciated with the development of breast cancer and they are also 
associated with survival and prognosis [22-26]. Even though 
immunohistochemical profiles of IMPCs are not used to dis-
criminate these tumors from other breast cancers, immuno-
histochemical studies can play an important role in treatment 
management and the indication of prognosis. 
There are some limitations in our study. First, the study lacks 
a control group composed of patients who were diagnosed with 
IDC, not otherwise specified (IDC, NOS). A comparison of 
IMPC with IDC, NOS should precede an analysis of the char-
acter of IMPC. A second limitation of this study is that it is 
retrospective, so not all patients underwent imaging of their 
tumors with all four modalities. 
In summary, imaging findings for IMPCs with mammo- 
graphy, US, and MRI are highly suggestive of malignancy, even 
though no features to distinguish IMPC from typical IDC were 
found. We identified the presence of frequent nodal metasta-
ses, high positivity of ER and c-erbB-2, and a high SUVmax 
value from PET-CT. These characteristics could be helpful in 
the treatment of and prognostic prediction for IMPCs.
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